what this node claims
AlphaFold metrics / GIPR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
78%structureusable
pLDDT 78.47
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 78.47
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 78.47
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
466 residues / min 26.89 / max 97.44 / source alphafold db
Very high
36.1%
168 residues / >=90
Confident
38.2%
178 residues / 70-89
Low
15.7%
73 residues / 50-69
Very low
10.1%
47 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 466 of 466 residues.
- residues 424-466 / mean 40.08
- residues 328-352 / mean 56.95
- residues 15-30 / mean 48.79
- residues 354-367 / mean 60.25
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.